SQZ Biotech has a promising new way of transforming cell behavior. This technology from MIT’s storied Langer Lab is backed by a $500 Million collaboration with Roche, the biggest maker of cancer drugs, and $24 million in VC money.
Sal Daher, CFA, together with other angels, is an investor in SQZ Biotech. To learn more about investing alongside Sal and his colleagues in this type of startup please enter your email address:
Investments in Startups are Inherently Risky. Such investments should only be undertaken by financially sophisticated persons who are accredited investors as defined under US securities laws and who are capable of bearing the risks involved. Do seek independent investment advice in making your decision to invest. We do not provide investment advice.
LISTEN TO SAL’S INTERVIEW OF ARMON SHAREI, CEO OF SQZ BIOTECH HERE
CURRENT PODCAST EPISODE
New Podcast Episodes Released Every Other Wednesday.
Timeless values of loyalty and integrity have helped Phillips Kuhl build a thriving company at the heart of one of the economy’s most innovative sectors: biotechnology. Holding more than 250 conferences per year, Cambridge Healthtech Institute or CHI, helps participants discover new perspectives on the problems they are addressing. This impressive feat requires the concerted effort of 150 talented employees whose encouragement and guidance are Phillips Kuhl’s constant concern. I really enjoyed discovering how my friend of long standing built his remarkable company.
New episodes released every Wednesday. Subscribe to our podcast on iTunes to make certain you never miss an episode: